The limited clinical data on MDSC-targeted therapy for cancer highlights an opportunity for investigating the anti-MDSC activity of routinely used anti-cancer drugs in combination with novel agents that target GM-CSF signalling. This evidence concerns the gene CSF2 and cancer.